Inovio Pharmaceuticals: Market Movements and Key Regulatory and Legal Developments
Stock Performance Overview
Inovio (ticker: INO) experienced a sharp decline of 20.79 % during a 24‑hour period that ended at 04:52 PM Central Europe on Thursday, 22 October 2026. The share price fell to approximately USD 0.88 on the Nasdaq exchange, where the company’s current market capitalization stands at USD 104.4 million. In the last 24 hours, roughly USD 9.2 million of Inovio shares changed hands, a figure that represents only 1.7 % of the total supply of 103.4 million shares.
Since the end of the previous month, Inovio’s stock has traded 37.98 % down, underscoring a period of sustained pressure on the company’s valuation. The 200‑day simple moving average sits at USD 1.29, well above the current trading level. Historically, Inovio’s price has oscillated between a 52‑week high of USD 2.72 (17 December 2025) and a 52‑week low of USD 0.56 (30 July 2026).
Regulatory Update: FDA Decision on INO‑3107
Inovio’s chief therapeutic candidate, INO‑3107, is pending a critical review by the U.S. Food and Drug Administration (FDA). The outcome of this review will determine whether the drug receives approval, potentially establishing Inovio as a new competitor to Precigen’s Papzimeos—currently the sole fully approved therapy for adults with recurrent respiratory papillomatosis. For stakeholders in the rare disease community, the FDA’s decision is of paramount importance, as it could broaden treatment options and alter the competitive landscape for this condition.
Legal Victory Against Competitors
Separately, Inovio secured a favorable judgment in litigation against VGXI and GeneOne Life Science. The court awarded Inovio substantial damages and legal costs, reinforcing the company’s intellectual‑property position and its commitment to protecting its technology and supply agreements. Inovio plans to pursue collection of the award; however, the financial stability of the defendants will influence the likelihood of full recovery. This legal outcome is expected to strengthen Inovio’s bargaining power with partners and competitors alike.
Contextual Performance of Related Stocks
In the same 24‑hour window, the following peers exhibited varying performance:
| Company | Trade % | Current Price (USD) | Market Cap (USD M) |
|---|---|---|---|
| Klx Energy Services (KLXE) | 0 % | 1.05 | 122.6 |
| Nkarta (NKTX) | +0.57 % | 1.76 | 124.6 |
| Definitive Healthcare (DH) | +1.77 % | 1.11 | 122.8 |
| Anavex Life Sciences (AVXL) | 0 % | 1.39 | 123.3 |
| Owlet (OWLT) | –1.87 % | 4.15 | 125.1 |
Anavex Life Sciences, in particular, reported significant progress in its clinical programs for blarcamesine (ANAVEX 2‑73). The company completed drug‑drug interaction (DDI) and ADME studies without serious adverse events, and the FDA has cleared an investigational new drug application for Fragile X syndrome. An upcoming FDA meeting in November aims to discuss expanding the Phase 3 Rett syndrome trial to include pediatric participants, underscoring a robust regulatory trajectory across its core indications.
Company Profile
Inovio Pharmaceuticals, Inc., headquartered in Plymouth Meeting, United States, specializes in the research and development of DNA vaccines for cancer, infectious diseases, and anti‑inflammatory indications, as well as animal health products. The company was founded in 1998 and has traded on the Nasdaq exchange since its initial public offering on February 12 1998. For additional information, visit the company’s website at www.inovio.com .
